Clinical Trial Detail

NCT ID NCT03485209
Title Efficacy and Safety Study of Tisotumab Vedotin for Patients With Solid Tumors
Recruitment Recruiting
Gender both
Phase Phase II
Variant Requirements no
Sponsors Seattle Genetics, Inc.
Indications

head and neck squamous cell carcinoma

pancreatic cancer

lung non-small cell carcinoma

colorectal cancer

Therapies

Tisotumab Vedotin

Age Groups: senior adult

No variant requirements are available.